To include your compound in the COVID-19 Resource Center, submit it here.

DEFINE-ing Boost

More data for BG-12 boosts Biogen Idec $4B; erases $4.5B from Teva in MS race

What a difference more data make. Biogen Idec Inc. (NASDAQ:BIIB) added $4 billion to its market cap last week when it announced detailed results from the Phase III DEFINE trial for oral multiple sclerosis candidate BG-12.

Investors shaved even more value - $4.5 billion - off Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), whose oral laquinimod also is in Phase III testing. Teva's partner, Active Biotech AB (SSE:ACTI), lost $70.8 million in market cap for the week.

Biogen Idec already had added $2.4 billion in market cap earlier this month when it announced that twice- and thrice-daily BG-12 met the primary endpoint in the DEFINE trial in relapsing-remitting MS. But because BG-12 required more than once-daily dosing and full data were not yet available, clinicians told BioCentury that once-daily laquinimod had the best chance of replacing injectables as SOC for first-line RRMS based on a combination of efficacy, safety and convenience (see BioCentury, April 18).

Last week's detailed results for DEFINE changed the picture.

On the primary endpoint, twice-daily BG-12 significantly reduced the proportion of patients who relapsed at two years by 49% vs. placebo (p<0.0001). On the secondary endpoints, BG-12 significantly reduced annualized relapse rate (ARR) and disability progression by 53% and 38%, respectively.

By comparison, once-daily laquinimod showed a 23% relative reduction in ARR from baseline to two years vs. placebo in the Phase III ALLEGRO trial in RRMS.

ARR was the primary endpoint in the study, which also released

Read the full 2358 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers